Esketamine was approved by the FDA in 2019 to treat depression that hasn’t responded to other treatment. Unlike oral antidepressants, which often take four to six weeks to take effect, esketamine is administered via nasal spray and becomes effective within hours.
It’s estimated that 5 million people in the United States have a depressive disorder that hasn’t resolved with current treatments. Esketamine may help those with treatment-resistant depression experience much-needed relief.
Omega was approved as a treatment center in the Summer of 2019. We are currently scheduling appointments for patients suffering from treatment-resistant depression. Please contact our office to see if you are a candidate for this program.
VISIT SPRAVATO